Would you recommend 10 years instead of 5 years of tamoxifen in a premenopausal woman with early stage, node negative ER/PR/HER2 positive breast cancer?  

Both the ATLAS and aTTom randomized controlled trials demonstrated that 10 years compared to 5 years of tamoxifen improves disease-free and overall survival among women with hormone receptor-positive early stage breast cancer. Most of the benefit was seen in the decrease in late breast cancer recurr...